Bone Health Supplement - for Bone Function Support (Eucommia, Rehmannia, Astragalus, Cuscuta)

Bone Health is a 100% natural supplement aimed at strengthening the bones. It contains four plant extracts in vegetarian capsules, traditionally used for their benefits in combatting bone loss: Astragalus membranaceus root, Cuscuta chinensis seeds, Eucommia ulmoides leaves and Rehmannia glutinosa root standardized to 2% flavonoids.

Research has shown that these four plants naturally help reduce the activity of osteoclasts (the bone resorption phase) and support that of osteoblasts (the bone formation phase).

Bone Health is the perfect complement to the bone function formulation Super Bone formula, which contains vitamins and minerals.

Who is Bone Health aimed at?

Bone Health is recommended for the following groups of people:

• Those aged over 40 (bone mass starts to decline by 1%-2% a year at this age).
• Menopausal women (during the post-menopause decade, bone loss speeds up by 2%-3% a year due to the fall in estrogen production).
• Those with a family history of osteoporosis-related fractures.
• Women who do little or no exercise.
• Those suffering from inflammatory bowel disease (Crohn’s).

What’s the reason for this bone loss?

Primarily linked to aging, osteoporosis is a natural process characterised by a decrease in bone mass and bone density. It makes bones more ‘porous’ and vulnerable to fractures from even simple falls. As bone loss does not normally produce any symptoms prior to a fracture, it is known as ‘the silent disease’. But why does this bone loss occur?

Our bones undergo constant remodelling throughout life via a two-fold process:

• A resorption phase during which specialized cells called ‘osteoclasts’ eat away at existing bone structures. This leads to the development of holes in the bones (called Howship lacunae).
• A new formation phase during which other specialized cells called ‘osteoblasts’ make new bone structures to compensate for the ‘holes’ and restore bones to a healthy state. Minerals then accumulate in the new matrix to optimise the bones’ mechanical resistance.

This dual process allows the body to be in constant harmony with its environment. In this way, damaged bones are quickly rebuilt and the body is even able to make stronger bones if environmental factors change (such as when we engage in a new physical activity). However, it’s important that this two-fold process remains in balance: if the resorption phase gains the upper hand, the ‘holes’ are never filled in and bones become dangerously fragile. This is exactly what happens in osteoporosis.

A number of factors affect the balance of this bone remodelling (1):

• Sex hormones. Estrogens are the main regulators of bone tissue remodelling. They target osteoblasts and are powerful inhibitors of bone resorption by osteoclasts. The fall in estrogen caused by the menopause leads to an enduring imbalance in bone renewal: gains start to be outweighed by losses and osteoporosis develops rapidly.
• Mechanical constraints. Bones are able to adapt according to the level of physical restraint to which they’re subjected. When you suddenly stop exercising, following an injury for example, physical stimulation stops, which increases the resorption phase and reduces the rebuilding phase. Physical inactivity is therefore a cause of osteoporosis over the long term.
• Bone Morphogenetic Proteins (BMPs). These are proteins which promote the bone formation phase.
• Transforming Growth Factor (TGF). This is a group of messengers that significantly influence the two phases of bone remodelling.
• Vitamin D. This vitamin plays an essential role in bone renewal: it stimulates intestinal absorption of calcium and phosphate (which are used to mineralise new bones) and inhibits parathormone, a protein that stimulates bone resorption.

What does the supplement Bone Health contain? What makes it so good for supporting bone remodelling?

Bone Health contains a blend of four plant extracts traditionally used for combatting bone loss.

Eucommia ulmoidesleaves

This is one of the most commonly prescribed natural treatments in China for treating osteoporosis (2-3). According to the theory of traditional Chinese medicine, Eucommia ulmoides (which is also called Du-Zhong in Asia) optimises the health of the kidneys which nourish and support bone tissue.

While modern science has demonstrated the anti-osteoporosis properties of Eucommia ulmoides, the mechanism of action is not yet clear. Several studies have shown that the plant’s non-steroidal polyphenolic lignans (4) behave in the same way as estrogens. These ‘phytestrogens’ may also bind to ‘estrogen receptor alpha’ (5-7), potentially upregulating the activity of a number of genes central to osteoblast function (8).

It is this mechanism which may explain their ability to stimulate the phase of bone formation by osteoblasts (9) and thus increase bone mineral density, without causing any side-effects (10).

Astragalus root

Astragalus is well-known for its adaptogen properties but this traditionally used plant has other strings to its bow. With a high content of flavonoids, particularly isoflavones (11), it has been used for thousands of years to counteract osteoporosis (12).

Research has shown that it acts on two factors involved in bone remodelling (13-14):

• It increases levels of TGF-β1, a growth factor which actively supports bone formation. This factor enables the recruitment, differentiation and proliferation of osteoblasts necessary for bone formation (15-16).
• It also reduces levels of TGF-α, another growth factor that plays an important role in bone resorption and strongly promotes bone destruction by osteoclasts. After the menopause, levels of TGF-β1 fall (17), contributing to the imbalance in bone remodelling.

Scientists believe that the isoflavones in Astragalus also interact with estrogen receptors. Like estrogens, they increase the absorption of calcium which is vital for bone remineralisation.

Cuscuta chinensis seeds.

Cuscuta chinensis is a parasitic plant that has been used in traditional medicine for thousands of years for supporting bone function. It is also known as Dodder and Tu-Si-Zi. Its mechanism of action appears to be very similar to that of Astragalus: Cuscuta chinensis also contains a number of flavonoids (18), the most active of which are kaempferol, quercetin, hyperoside, astragalin and lignans (19).

Studies show it supports osteoblast differentiation and proliferation while inhibiting osteoclast activity (20-21).

Extract of Rehmannia root

Rehmannia glutinosa is an edible plant commonly known as Dihuang, used for at least 3000 years in traditional medicine. Modern research has revealed the presence of numerous bioactive compounds including flavonoids and monoterpenoids (22). Catalpol appears to be the most effective of the monoterpenoids (23) for supporting bone function, though the precise mechanism has yet to be established.

Five good reasons to opt for Bone Health

1. Most of the drugs used for treating osteoporosis (biphosphonates, calcitonin, estrogens, fluoride, etc) cause problematic side-effects in the long term (osteonecrosis of the jaw, increased risk of certain cancers and several cardiovascular problems) (24-28). There is thus significant demand for natural products that are free from such side-effects.
2. Recent research shows it’s no coincidence that these four plant extracts are traditionally used to support bone function. They are all rich in phytestrogens, molecules that mimic estrogen activity and thus control several factors involved in bone remodelling.
3. This trademarked blend has been the subject of one in vitro and two in vivo studies. In all three cases, researchers observed a significant increase in biomarkers of bone formation as well as an improvement in resistance to fracture.
4. Bone Health acts synergistically with vitamins and minerals scientifically recognized as beneficial for bone health. While these substances are the elements needed for bone remineralisation, Bone Health enables the body to choose the right specification and help implement it effectively.
5. It contains only natural and safe texturing agents – rice flour and acacia fibre.

How and when should Bone Health be taken?

For significant long-term effects, supplementation should continue for a period of several months, at a dose of two capsules a day.

A number of additional measures can be taken:

• Supplementation with vitamin D, with calcium, or with other relevant substances available to buy at Supersmart (orthosilicic acid, and BMPs…).
• Frequent exposure to sunlight.
• Reducing consumption of caffeinated drinks (as they encourage calcium loss and thus the bone resorption phase).
• Taking up, or returning to, regular exercise (at an appropriate level for your physical condition).

The blend is very well-tolerated and is completely non-toxic.

Updated: February 2019.

Notes

This product should not be used as a substitute for a varied, balanced diet and a healthy lifestyle. It’s important to follow the guidelines on how to take it and the recommended dose, and to use it by the ‘best before’ date. It is not recommended for women who are pregnant or breastfeeding, or for children under 15. Keep out of children’s reach. Store in a cool, dry place.

Buy Bone Health for bone remodelling benefits.

1. Thomas T., Martin A., Lafage-Proust M.-H. Physiologie du tissu osseux. EMC (Elsevier Masson SAS, Paris), Appareil locomoteur, 14-002-B-10, 2008.
2. Kawasaki, T., Uezono, K., Nakazawa, Y., 2000. Antihypertensive mechanism of food for specified health use. “Eucommia leaf glycoside” and its clinical application. Journal of Health Science 22, 29–36.
3. Deyama, T., Nishibe, S., Nakazawa, Y., 2001. Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacologica Sinica 22, 1057–1070
4. Deyama, T., Nishibe, S., Nakazawa, Y., 2001. Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacologica Sinica 22, 1057–1070
5. Zhang, R., Pan, Y.-L., Hu, S.-J., Kong, X.-H., Juan, W., & Mei, Q.-B. (2014). Effects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitro. Journal of Ethnopharmacology, 155(1), 104–112. doi:10.1016/j.jep.2014.04.031
6. Yang, X.J., Wo, M.S., Wang, N.L., Chan, S.C., Yao, X.S., 2007. Lignans from the stems of Sambucus williamsii and their effects on osteoblastic UMR106 cells. Journal of Asian Natural Products Research 9, 583–591.
7. Jiang, M.M., Gao, H., Dai, Y., Zhang, X., Wang, N.L., Yao, X.S., 2009. Phenylpropanoid and lignan derivatives from Antiaris toxicaria and their effects on proliferation and differentiation of an osteoblast-like cell line. Planta Medica 75, 340–345.
8. Riggs, B.L., Hodgson, S.F., O'Fallon, W.M., Chao, E.Y., Wahner, H.W., Muhs, J.M., Cedel, S.L., Melton III, L.J., 1990. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New England Journal of Medicine 322, 802–809.
9. Ha, H., Ho, J., Shin, S., Kim, H., Koo, S., Kim, I.H., Kim, C., 2003. Effects of Eucommiae cortex on osteoblast-like cell proliferation and osteoclast inhibition. Archives of Pharmacal Research 26, 929–936
10. Zhang, R., Pan, Y.-L., Hu, S.-J., Kong, X.-H., Juan, W., & Mei, Q.-B. (2014). Effects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitro. Journal of Ethnopharmacology, 155(1), 104–112. doi:10.1016/j.jep.2014.04.031
11. Zheng Z, Liu D, Song C, Cheng C, Hu Z (1998) Studies on chemical constituents and immunological function activity of hairy root of Astragalus membranaceus. Chin J Biotechnol 14:93–97
12. Kim, C., Ha, H., Lee, J.H., Kim, J.S., Song, K., and Park, S.W. (2003). Herbal extract prevents bone loss in ovariectomized rats. Arch Pharm Res. 26:917-24.
13. Qu, Z.H., Yang, Z.C., Chen, L., Lv, Z.D., Yi, M.J., Ran, N. (2012). Inhibition airway remodeling and transforming growth factor-β1/Smad signaling pathway by astragalus extract in asthmatic mice. Int J Mol Med. 2012:564-8
14. Jung, Koo H., Sohn, E.H., Kim, Y.J., Jang, S.A., Namkoong, S., Chan Kang, S. (2013). Effect of the combinatory mixture of Rubus coreanus Miquel and Astragalus membranaceus Bunge extracts on ovariectomy-induced osteoporosis in mice and anti-RANK signaling effect. J Ethnopharmacol. 2014:951-9.
15. Wergedal, J.E., Matsuyama, T., and Strone, D.D. (1992). Differentiation of normal human bone cells by transforming growth factor-βand 1,25(OH)2 Vitamin D3. Metabolism. 41:42-48.
16. Ingram, R.T., Bonde, S.K., Riggs, B.L., and Fitzpatrick, L.A. (1994). Effects of transforming grouth factor beta(TGF beta ) and 1,25 dihydroxyvitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. Differentiation. 55:153-163.
17. Ikeda, T., Shigeno, C., Kasai, R., Kohno, H., Ohta, S., Okumura, H., Konishi, J., and Yamamuro, T. (1993). Ovariectomy decreases the mRNA levels of transforming growth factor-beta 1 and increases the mRNA levels of osteocalcin in rat bone in vivo. Biochem Biophys Res Commun. 194:1228-1233
18. Hou, D.Y., Li, T.C., Yu, B., 2003. Comparative study of volatile oil on Cuscuta 2 species. Journal of Chinese Mass Spectrometry Society 24, 343–345.
19. Williamson, G., Barron, D., Shimoi, K., Terao, J., 2005. In vitro biological properties of flavonoid conjugates found in vivo. Free Radical Research 39, 457–469.
20. Yao, C.H., Tsai, H.M., Chen, Y.S., Liu, B.S., 2005. Fabrication and evaluation of a new composite composed of tricalcium phosphate, gelatin, and Chinese medicine as a bone substitute. Journal of Biomedical Material Research part B Apply Biomaterial 75, 277–288
21. Yang, L., Chen, Q., Wang, F., Zhang, G., 2011. Antiosteoporotic compounds from seed of Cuscuta chinensis. Journal of Ethnopharmacology 135, 553–560.
22. Fu, G., Du, X., 2015. Research advance on chemical constituents and pharmacological activities of Rehmannia glutinosa China Medicine and Pharmacy 5, 21-23.
23. Lai, N., Zhang, J., Ma, X., Wang, B., Miao, X., Wang, Z., Guo, Y., Wang, L., Yao, C., Li, X., Jiang, G., 2015. Regulatory Effect of Catalpol on Th1/Th2 cells in Mice with Bone Loss Induced by Estrogen Deficiency. American journal of reproductive immunology 74, 487-498.
24. Stevenson, J.C., 2005. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 51, 113–126
25. Foidart, J.M., Desreux, J., Pintiaux, A., Gompel, A., 2007. Hormone therapy and breast cancer risk. Climacteric 2, 54–61.
26. Mørch, L.S., Løkkegaard, E., Andreasen, A.H., Krüger-Kjaer, S., Lidegaard, O., 2009. Hormone therapy and ovarian cancer. The Journal of the American Medical Association 302, 298–305.
27. Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D., Gagel, R.F., Gilsanz, V., Guise, T., Koka, S., McCauley, L.K., McGowan, J., McKee, M.D., Mohla, S., Pendrys, D.G., Raisz, L.G., Ruggiero, S.L., Shafer, D.M., Shum, L., Silverman, S.L., Van Poznak, C.H., Watts, N., Woo, S.B., Shane, E., American Society for Bone and Mineral Research, 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 22, 1479–1491.
28. O'Ryan, F.S., Lo, J.C., 2012. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. International Journal of Oral and Maxillofacial Surgery 70, 1844–1853.